Rottenstein Law Group Awaiting Outcome of FDA Panel Meeting to Discuss Fosamax Link to Throat Cancer
Rottenstein Law Group Awaiting Outcome of FDA Panel Meeting to Discuss Fosamax Link to Throat Cancer The Rottenstein Law Group, which represents clients with claims stemming from the severe side effects of the drug Fosamax, is eagerly awaiting the report of an FDA panel being convened in September to discuss Fosamax, and specifically whether the drug increases incidence of throat cancer. New York, NY (PRWEB) July 25, 2011 According to an article published by Bloomberg on July 21, in advance of an advisory panel meeting on September 9 to discuss the long-term safety of drugs used to treat
Contributor
About
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations
Categories
- Articles 308
- Bankruptcy 44
- Business 133
- Cases & Codes 68
- Contracts 27
- Criminal Law 122
- Employment 24
- Expert Reports 3
- Expert Witness 34
- Family Law 57
- Form Letters 15
- Immigration 3
- Intellectual Prop 32
- Internet Law 10
- Law Practice 99
- Law School 2
- Legal Research 19
- Litigation 186
- Miscellaneous 64
- PR Web 41689
- Personal Injury 608
- Press Release 43
- Probate 54
- Real Estate 68
- Tax Law 23
- Workers Comp 4